Zevra Therapeutics Receives Negative Opinion From EMA CHMP On Its Marketing Authorization Application For Arimoclomol For The Treatment Of Niemann-Pick Disease Type C

뉴스 본문을 불러오고 있어요.

Zevra Therapeutics Receives Negative Opinion From EMA CHMP On Its Marketing Authorization Application For Arimoclomol For The Treatment Of Niemann-Pick Disease Type C | 웨이프 WAPE

Zevra Therapeutics Receives Negative Opinion From EMA CHMP On Its Marketing Authorization Application For Arimoclomol For The Treatment Of Niemann-Pick Disease Type C

기사 요약

관련 종목

댓글 —